Event Recap: HK-SH Tripartite Joint Liver Forum 2025

HKUMed and National Cancer Institute jointly develop 'Cancer Immunology Data Engine' The most extensive data platform so far for advancing cancer immunotherapy research

Event Recap: SKLLR Symposium 2025

HKU ranked First in China for Female Scientists in Research.com rankings

Old drug, new use – HKUMed discovers cholesterol medication's potential as a novel treatment for liver cancer

Event Recap: SKLLR Internal Research Meeting 2025

HKUMed identifies key protein in liver cancer resistance and develops inhibitor to enhance therapy and prevent cancer recurrence

HKUMed launches world-leading gene-related therapy clinical trials to eradicate chronic hepatitis B infection

Officially renamed to 肝病研究全國重點實驗室 

HKUMed uncovers world's first 'hidden' peripheral neural stem cells, revolutionising regenerative medicine

HKUMed leads global drug development using new ‘dual immunotherapy’ in liver-cancer patients, improving survival benefits; receives international approvals

HKUMed reveals excess fat linked to liver cancer immunotherapy resistance: advocates healthier diets

Innovative HKUMed treatment results in complete long-term remission of advanced liver cancer without surgery in 46% of patients in study

SKLLR's Achievement at the 50th International Exhibition of Inventions in Geneva 2025

Event Recap: Theme-Based Research Scheme (TRS) Scientific Advisory Board Visit and Professor GS Feng's Seminar

HKUMed territory-wide studies reveal the benefits of optimal diabetes control in reducing the risk of colorectal and liver cancer by 30%

Event Recap: SKLLR Symposium 2024

Histotripsy technology: a non-invasive, painless, highly efficient surgery for liver cancer

Event Recap: Visit to CAS Center for Excellence in Molecular Cell Science, China

HKUMed's world-first 'Liver-in-Cube' wins a Gold medal at International Exhibition of Inventions of Geneva, advancing precise cancer treatment

Event Recap: Professor Gregg L. Semenza, Awardee of Nobel Prize in Physiology or Medicine in 2019, visited SKLLR

HKUMed and the Correctional Services Department launch a pilot programme for hepatitis C virus screening and treatment for eligible persons in custody on a voluntary basis

RTHK program “I & T New Era 創科新里程”

Academic Committee 

港大免疫療法拓治肝癌新徑 訂症狀分期方法成世界標準 (香港商報)

HKUMed identifies an important immune checkpoint leading into new treatment direction for liver cancer (Mirage News)

蛋白質「FUT1」增癌細胞耐藥性及復發機會　抑制可延緩肝癌復發 (東方日報)

港大研乙肝新藥可斷尾 (星島日報)

港大研究揭「胞外囊泡」致肝癌發展及擴散至肺部　新指標助早診斷 (HK01)

港大瑪麗醫院「先縮後除」療法助根治中晚期肝癌　料3年完成研究 (HK01)

Appointment of Academic Committee 

港大研「香港適用」治肝癌方案 (大公報)

肝癌新標靶治療月費3萬無資助   基金會計劃為中晚期肝癌患者免費用藥 (經濟日報)

港大研究︰乙肝患者近半不自知   收入愈低   甲肝戊肝感染率愈高 (明報)

丙肝患者肝癌風險高17倍 (蘋果日報)

免疫療法治肝癌 衝破癌細胞偽裝 成效高於傳統化療 (蘋果日報)

Renamed as “State Key Laboratory of Liver Research (The University of Hong Kong)”

A Delegation of the Department of S& T for Social Development (Ministry of Science and Technology) Visited The University of Hong Kong

State Key Laboratory of Liver Research has been graded “Outstanding” in the First Round of Reassessment of Partner State Laboratories

實驗室肝病誓趕絶乙肝病毒 (明報)

肝病實驗室硏針對癌症特有幹細胞治療 (東方日報)

教授鼓舞： 促進兩地產業互補化 資金獲批「過河」港大科研「喜飛」(大公報)

擒癌硏先擒「王」「點相」助製標靶藥 (文匯報)

[北水撐創科］港大兩國家重點實驗室有份：加強設備及集結大數據 (HK01)

肝癌關鍵基因港大揭秘 (東方日報)

Mainland – Hong Kong Academic Exchange 《京港學術交流》114期